A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

Completed · Phase 2 · Has a placebo group

Conditions studied: Macular Degeneration

In brief

This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.

Key facts

Study ID

NCT02181517

Run by

Allergan

People needed

25

Starts

2014-07-01

Expected to finish

2015-03-01

Last updated by the study team

2016-05-17

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of wet age-related macular degeneration in at least 1 eye
• Best corrected visual acuity of 20/32 to 20/320 in the study eye and 20/200 or better in the fellow eye

You may not qualify if…

• Hypersensitivity, allergy, or anaphylactic reaction to iodine
• Cataract or refractive surgery within the last 3 months
• History of vitrectomy

Where it is running

• Study site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.